(Q37834619)

English

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias

scientific article published on February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

0 references

Alzheimer's disease

1 reference

based on heuristic

inferred from title

biological psychiatry

1 reference

based on heuristic

inferred from title

3

object named as

Bengt Winblad

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Hans-Jürgen Möller

6

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

author name string

Ralf Ihl

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Lutz Frölich

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Lon Schneider

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Alistair Burns

5

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias

7

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

2-32

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The scandal of poor medical research

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Mild cognitive impairment: a cross-national comparison

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

How to grade categories of evidence.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthre

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The Diagnosis of Dementia in the Elderly a Comparison of CAMCOG (the Cognitive Section of CAMDEX), the AGECAT Program, DSM–III, the Mini-Mental State Examination and Some Short Rating Scales

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Forecasting the global burden of Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Interchanging scores between clinical dementia rating scale and global deterioration scale.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Agitated behaviors in the elderly. I. A conceptual review

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Ginkgo biloba for prevention of dementia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The effect of different diagnostic criteria on the prevalence of dementia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Mild cognitive impairment in the elderly: predictors of dementia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The clinical use of structural MRI in Alzheimer disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Clinical-neuropathological correlations in Alzheimer's disease and related dementias

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Management of behavioral problems in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Results, rhetoric, and randomized trials: the case of donepezil

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Prevalence and severity of cognitive impairment with and without dementia in an elderly population.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Neuroradiological findings in vascular dementia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Cerebral blood flow in dementia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Neurological complications of psychiatric drugs: clinical features and management

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Adverse effects of atypical antipsychotics : differential risk and clinical implications

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

CONSORT for reporting randomised trials in journal and conference abstracts

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Differential validity of psychometric tests in dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Improving safety reporting from randomised trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Antipsychotic drug use among elderly nursing home residents in the United States.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

[Ginkgo biloba extract EGb 761 in the treatment of dementia: evidence of efficacy and tolerability].

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

World psychiatric association section of old age psychiatry consensus statement on ethics and capacity in older people with mental disorders

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Quetiapine for agitation or psychosis in patients with dementia and parkinsonism

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Effectiveness of an individualized functional training program on affective disturbances and functional skills in mild and moderate dementia--a randomized control trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Frontotemporal dementia: a randomised, controlled trial with trazodone

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Carbamazepine treatment of agitation associated with dementia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Drug-induced, dementia-associated and non-dementia, non-drug delirium hospitalizations in the United States, 1998-2005: an analysis of the national inpatient sample.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Absence of vascular dementia in an autopsy series from a dementia clinic.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The use of PET in Alzheimer disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Psychosocial treatments of behavior symptoms in dementia: a systematic review of reports meeting quality standards.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Psychosocial treatments of psychological symptoms in dementia: a systematic review of reports meeting quality standards.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Mild cognitive impairment as a diagnostic entity

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The hope and the hazards of using compliance data in randomized controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendations

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

How well are clinicians following dementia practice guidelines?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Meta-analysis: recent developments in quantitative methods for literature reviews.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Sertraline for the treatment of depression in Alzheimer disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Clinical neurophysiology of aging brain: from normal aging to neurodegeneration

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

What errors do peer reviewers detect, and does training improve their ability to detect them?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Behavioral and psychological symptoms associated with dementia subtype and severity

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Effectiveness of standardized ginkgo biloba extract on cognitive symptoms of dementia with a six-month treatment: a bivariate random effect meta-analysis.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Donepezil in vascular dementia: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Improving the reporting of pragmatic trials: an extension of the CONSORT statement

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2010.538083

21 January 2018

Identifiers

10.3109/15622975.2010.538083

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37834619&oldid=2102741572"